Sanofi invests $20B to expand pharmaceutical manufacturing capacity in the United States
Sanofi has announced plans to invest at least $20 billion through 2030 to expand its pharmaceutical manufacturing operations in the United States. The company, which develops and produces medicines and vaccines, will allocate billions of dollars to manufacturing expansion while also significantly increasing its research and development spending.
The planned investment is expected to support the launch of numerous new first- or best-in-class medicines across a range of therapeutic areas. Sanofi’s expansion will include direct investments in its own U.S. facilities and partnerships with other domestic manufacturers, contributing to an enhanced supply chain for critical medicines. While specific locations and job numbers were not disclosed, the company anticipates the creation of a significant number of high-paying jobs across multiple states.
What people are saying
In a recent quote, Paul Hudson, Chief Executive Officer, Sanofi, said, “Sanofi's 13,000 US-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas. Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US.”
Investing in American manufacturing in 2025
This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.